Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice

Journal of Neurochemistry

Volumn 114, Issue 6, 2010, Pages 1619-1629

  Ding, Jing ^a   Li, Qin Ying ^a   Wang, Xin ^a   Sun, Chang Hai ^b   Lu, Chuan Zhen ^a   Xiao, Bao Guo ^a  

^a FUDAN UNIVERSITY   (China)

^b Tianjin Chase Sun Pharmaceutical Co Ltd   (China)

Author keywords

anti inflammation; Fasudil; microglia; neuroprotection; Rho kinase inhibitor hypoxia reoxygenation

Indexed keywords

FASUDIL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; RHO KINASE; RHO KINASE II; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; CYTOKINE; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN TISSUE; CELL DAMAGE; CYTOKINE PRODUCTION; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MOUSE; HIPPOCAMPUS; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; DRUG EFFECTS; HYPOXIA, BRAIN; INFLAMMATION; METABOLISM; NEWBORN; PATHOLOGY; PHYSIOLOGY;

MUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASTROCYTES; CELL HYPOXIA; CELLS, CULTURED; CYTOKINES; EMBRYO, MAMMALIAN; HIPPOCAMPUS; HYPOXIA, BRAIN; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; OXYGEN; RHO-ASSOCIATED KINASES;

EID: 77956307191     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06876.x     Document Type: Article

References (38)

1. Borisoff J. F., Chan C. C., Hiebert G. W., Oschipok L., Robertson G. S., Zamboni R., Steeves J. D. Tetzlaff W. (2003) Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol. Cell. Neurosci. 22, 405 416.
2. Brabeck C., Beschorner R., Conrad S., Mittelbronn M., Bekure K., Meyermann R., Schluesener H. J. Schwab J. M. (2004) Lesional expression of RhoA and RhoB following traumatic brain injury in humans. J. Neurotrauma 21, 697 706.
3. Broughton B. R., Walker B. R. Resta T. C. (2008) Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L797 L806.
4. Brown G. C. Bal-Price A. (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27, 325 355.
5. Cheng C., Webber C. A., Wang J., Xu Y., Martinez J. A., Liu W. Q., McDonald D., Guo G. F., Nguyen M. D. Zochodne D. W. (2008) Activated RHOA and peripheral axon regeneration. Exp. Neurol. 212, 358 369.
6. Coleman M. L., Sahai E. A., Yeo M., Bosch M., Dewar A. Olson M. F. (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat. Cell Biol. 3, 339 345.
7. Correa F., Hernangomez M., Mestre L., Loria F., Spagnolo A., Docagne F., Di M. V. Guaza C. (2010) Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 58, 135 147.
8. Deyts C., Galan-Rodriguez B., Martin E., Bouveyron N., Roze E., Charvin D., Caboche J. Bétuing S. (2009) Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS ONE 4, e8287.
9. He Y., Xu H., Liang L., Zhan Z., Yang X., Yu X., Ye Y. Sun L. (2008) Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum. 58, 3366 3376.
10. Homma N., Nagaoka T., Morio Y., Ota H., Gebb S. A., Karoor V., McMurtry I. F. Oka M. (2007) Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J. Cardiovasc. Pharmacol. 50, 697 702.
11. Honing H., van B. T., van P. S., Dijkstra C. D., van K. R., Collard J. G. de V. H. (2004) RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukoc. Biol. 75, 523 528.
12. Huang L., He Z., Guo L. Wang H. (2008) Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase. Cell. Mol. Neurobiol. 28, 757 768.
13. Ito T., Ohtori S., Hata K., Inoue G., Moriya H., Takahashi K. Yamashita T. (2007) Rho kinase inhibitor improves motor dysfunction and hypoalgesia in a rat model of lumbar spinal canal stenosis. Spine 32, 2070 2075.
14. Julien S., Schnichels S., Teng H., Tassew N., Henke-Fahle S., Mueller B. K. Monnier P. P. (2008) Purkinje cell survival in organotypic cultures: implication of Rho and its downstream effector ROCK. J. Neurosci. Res. 86, 531 536.
15. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y. Oshima H. (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9, 2632 2641.
16. Koyanagi M., Takahashi J., Arakawa Y., Doi D., Fukuda H., Hayashi H., Narumiya S. Hashimoto N. (2008) Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. J. Neurosci. Res. 86, 270 280.
17. Kubo T. Yamashita T. (2007) Rho-ROCK inhibitors for the treatment of CNS injury. Recent Pat. CNS Drug Discov. 2, 173 179.
18. Kubo T., Yamaguchi A., Iwata N. Yamashita T. (2008) The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther. Clin. Risk Manag. 4, 605 615.
19. Lepley D., Paik J. H., Hla T. Ferrer F. (2005) The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 65, 3788 3795.
20. Li Q., Huang X. J., He W., Ding J., Jia J. T., Fu G., Wang H. X. Guo L. J. (2009) Neuroprotective potential of fasudil mesylate in brain ischemia-reperfusion injury of rats. Cell. Mol. Neurobiol. 29, 169 180.
21. Lingor P., Teusch N., Schwarz K., Mueller R., Mack H., Bahr M. Mueller B. K. (2007) Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 103, 181 189.
22. Mallat Z., Gojova A., Sauzeau V., Brun V., Silvestre J. S., Esposito B., Merval R., Groux H., Loirand G. Tedgui A. (2003) Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93, 884 888.
23. McCoy M. K. Tansey M. G. (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation. 5, 45.
24. Mills J. C., Stone N. L., Erhardt J. Pittman R. N. (1998) Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J. Cell Biol. 140, 627 636.
25. Minghetti L. (2005) Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18, 315 321.
26. Mueller B. K., Mack H. Teusch N. (2005) Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387 398.
27. Noma K., Oyama N. Liao J. K. (2006) Physiological role of ROCKs in the cardiovascular system. Am. J. Physiol. Cell Physiol. 290, 661 668.
28. Riento K. Ridley A. J. (2003) Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4, 446 456.
29. Rikitake Y., Kim H. H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M. A. Liao J. K. (2005) Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36, 2251 2257.
30. Sebbagh M., Renvoize C., Hamelin J., Riche N., Bertoglio J. Breard J. (2001) Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 3, 346 352.
31. Sen N., Hara M. R., Kornberg M. D. et al. (2008) Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 10, 866 873.
32. Shimokawa H. Takeshita A. (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 25, 1767 1775.
33. Simi A., Tsakiri N., Wang P. Rothwell N. J. (2007) Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 35, 1122 1126.
34. Suzumura A., Takeuchi H., Zhang G., Kuno R. Mizuno T. (2006) Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann. N Y Acad. Sci. 1088, 219 229.
35. Uehata M., Ishizaki T., Satoh H. et al. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990 994.
36. Watanabe K., Ueno M., Kamiya D. et al. (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681 686.
37. Yamashita K., Kotani Y., Nakajima Y., Shimazawa M., Yoshimura S., Nakashima S., Iwama T. Hara H. (2007) Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res. 1154, 215 224.
38. Zhang Z., Fauser U. Schluesener H. J. (2008) Dexamethasone suppresses infiltration of RhoA+ cells into early lesions of rat traumatic brain injury. Acta Neuropathol. 115, 335 343.